Pipeline

Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept IL-1α & IL-1β Recurrent pericarditis
(breakthrough therapy designation)
Mid Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab GM-CSFRα Giant cell arteritis Phase 2
Worldwide
Relapsed or refractory large B-cell lymphoma* End Phase 1
Worldwide
KPL-716 OSMRβ Prurigo nodularis Phase 2
Worldwide
Multi-indication pilot study in diseases with a chronic pruritic component Phase 2
Worldwide
KPL-404 CD40 T-cell dependent, B-cell–mediated indications Phase 1
Worldwide
*Collaboration with Kite, a Gilead Company.

Every Second Counts!